Today Biogen Idec BIIB announced new data from studies
evaluating oral BG-12 (dimethyl fumarate), which provide further
evidence supporting its strong clinical and radiological effects in
people with relapsing-remitting multiple sclerosis (RRMS) and reinforce
its favorable safety profile seen to date. These data were presented at
the 28th Congress of the European Committee for the Treatment
and Research of Multiple Sclerosis (ECTRIMS) in Lyon, France.
In a pre-specified analysis of integrated, or pooled, data from the
Phase 3 DEFINE and CONFIRM studies, dimethyl fumarate showed
statistically significant and clinically relevant effects in reducing
multiple sclerosis (MS) relapses and progression of disability, as well
as reductions in magnetic resonance imaging (MRI) measures of disease
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in